Although there is a strong concordance between FDG and PSMA uptake in the initial diagnosis of high-grade gliomas and evaluation of tumor recurrences, PSMA-targeting radiopharmaceuticals were found to be more accurate than FDG, due to the absence of physiological radiopharmaceutical uptake in normal brain parenchyma [47,48]. The gene discussed is FOLH1; the disease is central nervous system cancer.